Delivery Order SPE2DB20D3103-SPE2DB25FP6X6
- Not listed
- The Defense Logistics Agency awarded a $2,287.74 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injectors on July 25, 2025, with an ultimate completion date of July 28, 2025. This delivery order was competitively awarded with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $4,964.46 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on July 22, 2025. This competitively awarded, firm fixed-price delivery order is set to be completed by July 23, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a glucagon-like peptide-1 receptor agonist used for weight management and diabetes treatment, reflecting the Defense...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors, with a contract ceiling value of $15,256.35 and an ultimate completion date of July 21, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a branded GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a $1,143.87 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on July 18, 2025, with completion targeted for July 21, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement executed by the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections with a ceiling value of $1,586.80. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a diabetes and weight management medication,...
- The Defense Logistics Agency awarded a delivery order valued at $42,562.60 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on July 30, 2025, with completion targeted for July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the federal government's...
- The Defense Logistics Agency (DLA) awarded a $4,043.29 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injectors on July 30, 2025, with a completion date of July 31, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The product will be delivered to AmerisourceBergen's Corporate Office location in...
- The Defense Logistics Agency awarded a delivery order valued at $8,512.52 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This firm fixed-price, non-competitive set-aside delivery order is scheduled for completion by July 29, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, representing part of the federal government's pharmaceutical...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP6X6Delivery Order
The Defense Logistics Agency awarded a $2,287.74 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injection on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a single-line item pharmaceutical procurement fulfilled from AmerisourceBergen's existing contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication indicated for weight management and represents the type of specialized pharmaceutical product the Defense Logistics Agency procures to support military and federal healthcare systems. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a child contract to this prime vehicle, the award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting the Defense Health Agency and other federal healthcare programs globally. The company's IDC encompasses a comprehensive range of pharmaceutical products, medical supplies, vaccines, and specialty medications across multiple therapeutic domains, enabling flexible fulfillment of federal medical procurement requirements through this established contracting mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 7/30/25 |